Boston, MA 06/04/2014 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) is a globally recognized heath care company, which provides innovative heath products across the globe. The company is familiar in the name of MSD outside the U.S. and Canada. On Monday, June 2, 2014 the company declared that the highly anticipated immunotherapy proved its usefulness on the patients diagnosed with lung cancer, neck or head cancer and advanced melanoma.
Company Applied For FDA’s Approval:
In January, the company applied for approval to the U.S. Food and Drug Administration (FDA) for its MK3475 or Pembrolizumab, as a treatment for the skin cancer, melanoma. However, the drug’s largest sale is expected for treating lung cancer for which every year huge percentage of deaths are registered in the U.S.
About The Drug:
The work procedure of the drug is quite interesting. This innovative drug blocks the Programmed Death receptor or PD, which is used by the cancer cells inside the body to collapse the immune system. In a survey, it has been reported that the estimated highest annual sales of Pembrolizumab can reach $6 billion.
Research Facts:
Merck & Co., Inc. (NYSE:MRK)’s phase-I study on 411 patients suffering from melanoma concluded that almost 69% patients were alive after a span of one year. After 18 months the success rate was approximately 62%. The company presented the research report to the ‘American Society of Clinical Oncology’ meeting, which was organized in Chicago.
Patients diagnosed with metastatic melanoma most of the time have the upper limit of PD-L1 protein in the tumors, which bind with the receptor PD-1 in the immune cells and hide in the immune system. The drugs used on the patients during that time could not affect as it slow down the interaction.
Prof. of University of California Stated:
Dr. Antoni Ribas, the professor of hematology-oncology of the University of California stated that the drug is probably the safest among the drugs invented to treat metastatic melanoma.
